CompletedPHASE2, PHASE3NCT01496274

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: CSL Behring
Principal Investigator: Program Director
CSL Behring
Intervention: rIX-FP(biological)
Enrollment: 63 enrolled
Eligibility: 12-65 years · MALE
Timeline: 2012

Study locations (30)

Rush University Medical Center, Chicago, Illinois, United States
Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, Indiana, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
BloodCenter of Wisconsin, Milwaukee, Wisconsin, United States
AKH Wien [Hämatologie, Hämostaseol, Vienna, Austria
SHAT "Joan Pavel" OOD [Hemorrhagic Diathesis and Anemia], Sofia, Bulgaria
Centre Hospitalier Universitaire de Brest/CHU Morvan, Brest, France
C.R.T.H. Hôp. Bicêtre-Hémophilie, Le Kremlin-Bicêtre, France
CHU de Lyon - Hôpital Edouard Herriot [Hemophilie], Lyon, France
Hôpital Necker-CRTH, Paris, France
Instit. für Experimentelle - Hämato & Transfusionsmedizin, Bonn, Germany
Zentralkrankenhaus Prof. Hess-Kinderklinik, Bremen, Germany
Unikinderklinik Frankfurt/Main [Kinderheilkunde], Frankfurt, Germany
Universitätsklinikum Hamburg-Eppendorf, Abt für Pädiatr. Hämatologie, Hamburg, Germany
Werlhof-Inst. Hannover, Hanover, Germany
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01496274 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials